doi: 10.1161/ATVBAHA.106.130260
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Editorials |
Hormone Replacement Therapy and Atherosclerosis in Postmenopausal Women
Does Aging Limit Therapeutic Benefits?
From the Department of Internal Medicine, Internal Medicine I, Medical Policlinic, University Hospital Zurich, Switzerland.
Correspondence to Matthias Barton, MD, University Hospital Zurich, Department of Internal Medicine, Internal Medicine I, Medical Policlinic, Rämistrasse 100, CH-8091 Zürich, Switzerland. E-mail barton{at}usz.ch
Despite the clear-cut epidemiological evidence of protective effects of endogenous estrogens in premenopausal women,1,2 the results of randomized clinical trials using conjugated equine estrogens and medroxyprogesterone acetate instead of natural hormones have led to a paradigm shift in the usefulness of hormone treatment in postmenopausal women.3,4 One of the main criticisms in addition to the types of drugs chosen for treatment was the age of the patients. Indeed, in both WHI trial and HERS study, treatment of patients was initiated in women many years beyond menopause.5 In fact, the number of years since menopause was an independent indicator for nonfatal myocardial infarction or coronary related death.5 In this context, it appears of interest that heart disease may contribute to menopausal age and that menopausal age actually may be an indicator of cardiovascular risk.6,7
See page 1782
It was noted as early as 1952 that the natural endogenous estrogen 17ß-estradiol inhibits experimental atherosclerosis,8 and oral estrogens were even unsuccessfully evaluated to treat coronary artery disease in male patients.9–11 However, at the time little was known about the mechanisms by which sex steroid hormones affect vascular homeostasis and thrombogenesis. During the past 2 decades, considerable advances were made in the understanding of how natural estrogens act on the vasculature. 17ß-estradiol causes rapid and endothelium-independent dilation of coronary arteries of men and women,12 and chronic treatment with 17ß-estradiol inhibits experimental atherosclerosis in males and females.13,14 On the other hand, treatment with conjugated equine estrogens, which contain more than 30 different steroid compounds including testosterone and substances of still undefined vascular activity (Table), have shown less favorable effects,2–4 as has been reported for the synthetic progestin medroxyprogesterone acetate.15 With the identification of molecular targets of 17ß-estradiol and other estrogens it now appears that estrogen receptor 
represents the predominant target mediating the beneficial effects of 17ß-estradiol,2,14,16 although novel isoforms of estrogen receptor ß17 and novel targets such as GPR3018,19 have been identified. It is still unclear to what extent aging itself in the presence of coronary artery disease has any effects on vascular signaling and responsiveness to natural estrogen in postmenopausal women (Figure).
|
|
In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Sherwood et al present results of a double-blind, crossover randomized clinical study investigating the short-term effects of transdermally administered 17ß-estradiol alone or in combination with norethindrone acetate or placebo on flow-mediated endothelium-dependent dilation in women with documented coronary artery disease shortly and many after menopause. The authors studied more than 100 postmenopausal women and found that aging, but not the presence of coronary artery disease, was a determinant of the beneficial effects of hormone treatment. Interestingly, only the treatment with 17ß-estradiol but not the combination of 17ß-estradiol and norethindrone acetate had a positive effect on endothelium-dependent vasoreactivity in younger postmenopausal women, whereas in older postmenopausal women neither treatment was effective, regardless of the presence of coronary artery disease. Importantly, endothelium-dependent vasomotion was preserved in younger postmenopausal women despite the presence of coronary artery disease.
Why are these findings important? (1) A very rigid study design was used to address the questions reducing bias to a minimum; (2) This study is the first to systematically compare effects of hormone treatment in postmenopausal women in 2 defined age groups; (3) The data show that hormone replacement with a natural estrogen can improve peripheral arterial vascular function even in the presence of angiographically documented coronary artery disease. The results presented by Sherwood et al indicate that the beneficial effects of 17ß-estradiol on vascular function occur within hours, comparable to what has been shown in premenopausal women during different stages of the menstrual cycle.20,21 A question that remains is whether such short-term effects of hormone replacement therapy also affect function or structure of arteries other than the brachial artery, which in humans is less likely to develop atherosclerotic lesions than coronary or carotid arteries.22 At least in vitro studies suggest that short-term treatment with 17ß-estradiol also augments endothelium-dependent relaxation in human coronary arteries23 and that the sex steroid is responsible for the attenuated endothelium-dependent relaxation after acute estrogen withdrawal in coronary arteries.24 Another important issue arising from the results presented by Sherwood et al is the question whether hormone "replacement" therapy using 17ß-estradiol25 may have beneficial effects on the development of coronary atherosclerosis compared with the use of conjugated equine estrogens as in the HERS study and the WHI trial.26,27 Indeed, previous studies investigated whether chronic treatment with 17ß-estradiol for a period of up to 3 years affects the progression of subclinically or clinically relevant atherosclerosis in the carotid or coronary arteries in postmenopausal women.28,29 In these studies, Hodis and coworkers investigated the effects of 17ß-estradiol treatment on changes in intima-media thickness of the common carotid artery in postmenopausal women without evidence for ischemic heart disease and observed that treatment halted the progression of intimal thickening compared with placebo.28 Interestingly, the age of the patients was approximately 60 years. In the WELL-HART study the effects of chronic 17ß-estradiol treatment in patients with documented advanced atherosclerosis as coronary artery disease over a period of 3.3 years were investigated.29 Patients were again older (mean age, 63.5 years) and on average 2 decades past menopause.29 Similar to the study presented by Sherwood et al reporting no effects on endothelium-dependent vasomotion in the brachial artery of older women, the WELL-HART study found no effect on established coronary atherosclerosis after 17ß-estradiol treatment in older postmenopausal women.29 Interestingly, most recent studies suggest that hormone treatment may improve cardiovascular risk in younger postmenopausal women even when using conjugated equine estrogens.30,31
The data presented by Sherwood et al have important implications for cardiovascular medicine in general and the issue of hormone replacement therapy in particular. Based on the results of the randomized trials HERS and WHI using conjugated equine estrogens and medroxyprogesterone acetate as hormone therapy,3,4 guidelines on the use of postmenopausal hormone replacement therapy in patients with cardiovascular disease have been published by the National societies, including the American Heart Association.32–34 At a second look, it is not surprising that the use of drugs of unknown activities such as conjugated equine estrogens (Table) and medroxyprogesterone acetate, which is actually also used for chemotherapy,35,36 have resulted in adverse outcomes. Therefore, the question whether hormone "replacement" therapy with natural sex steroids25 may affect the course of atherosclerotic vascular disease cannot be currently answered (Figure). Future research should be directed not only toward deciphering the molecular mechanisms by which targets of estrogen regulate cardiovascular homeostasis, but also in the investigation of using natural steroids at lower doses, possibly using intermittent administration mimicking the menstrual cycle, long before the body has adjusted to the withdrawal of endogenous estrogens for many years.37 Prospective clinical trials are currently underway to address these issues, including the KEEPS study conducted by the Kronos Longevity Research Institute38 and the ELITE study performed at the University of California.39 Up to now, research indicates that using high-dosed regimens of sex steroids of unknown activity in postmenopausal women increases cardiovascular mortality, involving numerous mechanisms.40,41 The availability of clear-cut studies like the one by Sherwood et al will contribute to a more profound understanding of how natural estrogens modulate vascular function and atherogenesis (Figure). At the same time, it will be equally important to rigidly identify and treat known cardiovascular risk factors such as hyperlipidemia, hypertension, and obesity, which are independent predictors of coronary artery disease in women.2,42 Finally, information for patients about possibilities to improve cardiovascular health and prognosis such as simple changes in lifestyle including maintaining normal body weight, a healthy diet, and regular physical exercise should be intensely communicated.43
 |
Acknowledgments |
|---|
Sources of Funding
Work by the authors is supported by the Swiss National Foundation (3200-058426.99, 3232-058421.99, and 3200-108258/1), and the Hanne Liebermann Stiftung Zürich.
Disclosures
None.
|
Footnotes |
|---|
Parts of this work were presented at the workshop "Sex Hormones, Gender, and Hypertension—Molecular Mechanisms and Clinical Implications" at the American Heart Association’s 60th Annual Fall Conference and Scientific Sessions of the Council of High Blood Pressure Research, San Antonio, TX, October 4, 2006.
|
References |
|---|
 Top References |
|---|
1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999; 340: 1801–1811.
2. Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006; 47: 1019–1026.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc. 1998; 280: 605–613.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. J Am Med Assoc. 2002; 288: 321–333.
5. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005; 66: 295–306.
6. Bittner V. Menopause and cardiovascular risk cause or consequence? J Am Coll Cardiol. 2006; 47: 1984–1986.
7. Kok HS, van Asselt KM, van der Schouw YT, van der Tweel I, Peeters PH, Wilson PW, Pearson PL, Grobbee DE. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol. 2006; 47: 1976–1983.
8. Pick R, Stamler J, Rodbard S, Katz LN. The inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks. Circulation. 1952; 6: 276–280.[Medline] [Order article via Infotrieve]
9. Marmorston J, Magdison O, Kuzma O, Moore FJ. Estrogen therapy in men with myocardial infarction. Side-effects with increasing dosage and time. J Am Med Assoc. 1960; 174: 241–244.
10. Marmorston J, Moore FJ, Hopkins CE, Kuzma OT, Weiner J. Clinical studies of long-term estrogen therapy in men with myocardial infarction. Proc Soc Exp Biol Med. 1962; 110: 400–408.[CrossRef][Medline] [Order article via Infotrieve]
11. Stamler J, Pick R, Katz LN, Pick A, Kaplan BM, Berkson DM, Century D. Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. J Am Med Assoc. 1963; 183: 632–638.
12. Mügge A, Riedel M, Barton M, Kuhn M, Lichtlen PR. Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc Res. 1993; 27: 1939–1942.[Medline] [Order article via Infotrieve]
13. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E- deficient mice. Proc Natl Acad Sci U S A. 1996; 93: 10022–10027.
14. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol’s atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest. 2001; 107: 333–340.[Medline] [Order article via Infotrieve]
15. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997; 3: 324–327.[CrossRef][Medline] [Order article via Infotrieve]
16. Pepine CJ, Nichols WW. Estrogen and different aspects of vascular disease in women and men. Circ Res. 2006; 99: 459–461.
17. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A. 2006; 103: 13162–13167.
18. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005; 146: 624–632.[Medline] [Order article via Infotrieve]
19. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005; 307: 1625–1630.
20. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H, Ouchi Y. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation. 1995; 92: 3431–3435.
21. English JL, Jacobs LO, Green G, Andrews TC. Effect of the menstrual cycle on endothelium-dependent vasodilation of the brachial artery in normal young women. Am J Cardiol. 1998; 82: 256–258.[CrossRef][Medline] [Order article via Infotrieve]
22. Sorensen KE, Kristensen IB, Celermajer DS. Atherosclerosis in the human brachial artery. J Am Coll Cardiol. 1997; 29: 318–322.[Abstract]
23. Barton M, Cremer J, Mugge A. 17Beta-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur J Pharmacol. 1998; 362: 73–76.[CrossRef][Medline] [Order article via Infotrieve]
24. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation. 1994; 90: 1964–1968.
25. Barton M, Dubey RK. Postmenopausal hormone-replacement therapy. N Engl J Med. 2002; 346: 63–65.[CrossRef][Medline] [Order article via Infotrieve]
26. Klaiber EL, Vogel W, Rako S. A critique of the Women’s Health Initiative hormone therapy study. Fertil Steril. 2005; 84: 1589–1601.[CrossRef][Medline] [Order article via Infotrieve]
27. Mandavilli A. Hormone in the hot seat. Nat Med. 2006; 12: 8–9.[CrossRef][Medline] [Order article via Infotrieve]
28. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001; 135: 939–953.
29. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, Cashin-Hemphill L, Sanmarco ME, French WJ, Shook TL, Gaarder TD, Mehra AO, Rabbani R, Sevanian A, Shil AB, Torres M, Vogelbach KH, Selzer RH. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003; 349: 535–545.
30. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R. Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Intern Med. 2006; 166: 357–365.
31. Alexandersen P, Tanko LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2–3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric. 2006; 9: 108–118.[CrossRef][Medline] [Order article via Infotrieve]
32. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004; 109: 672–693.
33. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabumni RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL. Summary of the American Heart Association’s evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler Thromb Vasc Biol. 2004; 24: 394–396.
34. Gohlke-Barwolf C, Regitz-Zagrosek V, Mueck AO, Strasser RH. [The value of hormone replacement therapy for prevention of coronary heart disease in women]. Z Kardiol. 2002; 91: 430–435.[CrossRef][Medline] [Order article via Infotrieve]
35. Diament MJ, Peluffo GD, Stillitani I, Cerchietti LC, Navigante A, Ranuncolo SM, Klein SM. Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer Invest. 2006; 24: 126–131.[CrossRef][Medline] [Order article via Infotrieve]
36. Watanabe J, Watanabe K, Jobo T, Kamata Y, Kawaguchi M, Imai M, Okayasu I, Kuramoto H Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer. 2006; 16 Suppl 1: 452–457.[Medline] [Order article via Infotrieve]
37. Barton M. Postmenopausal oestrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection. Expert Opin Investig Drugs. 2001; 10: 789–809.[CrossRef][Medline] [Order article via Infotrieve]
38. Internet: http://www.clinicaltrials.gov/show/NCT00154180 (accessed September 11, 2006).
39. Internet: http://www.clinicaltrials.gov/show/NCT00114517 (accessed September 11, 2006).
40. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol. 2006; 47: 1741–1753.
41. Women’s Health Initiative: not over yet. The largest study of women’s health has raised at least as many questions as it has answered. Stay tuned. Harv Womens Health Watch. 2006; 13: 1–4.[Medline] [Order article via Infotrieve]
42. Gierach GL, Johnson BD, Bairey Merz CN, Kelsey SF, Bittner V, Olson MB, Shaw LJ, Mankad S, Pepine CJ, Reis SE, Rogers WJ, Sharaf BL, Sopko G. Hypertension, menopause, and coronary artery disease risk in the Women’s Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol. 2006; 47: S50–58.
43. Barton M. Aging and biomedicine 2005: where should we go from here? Cardiovasc Res. 2005; 66: 187–189.
44. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005; 308: 1583–1587.
Related Article:
Arterioscler Thromb Vasc Biol 2007 27: 1782-1787.
This article has been cited by other articles:
 |
|
 |
|
  K. M. Gavin, D. R. Seals, A. E. Silver, and K. L. Moreau Vascular Endothelial Estrogen Receptor {alpha} Is Modulated by Estrogen Status and Related to Endothelial Function and Endothelial Nitric Oxide Synthase in Healthy Women J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3513 - 3520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Meyer and M. Barton ER{alpha}, ER{beta}, and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis Cardiovasc Res, September 1, 2009; 83(4): 605 - 610. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Barton and M. R. Meyer Postmenopausal Hypertension: Mechanisms and Therapy Hypertension, July 1, 2009; 54(1): 11 - 18. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Xing, S. Nozell, Y.-F. Chen, F. Hage, and S. Oparil Estrogen and Mechanisms of Vascular Protection Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pretorius, G. P. van Guilder, R. J. Guzman, J. M. Luther, and N. J. Brown 17{beta}-Estradiol Increases Basal but Not Bradykinin-Stimulated Release of Active t-PA in Young Postmenopausal Women Hypertension, April 1, 2008; 51(4): 1190 - 1196. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||